TATA Health International Holdings released its interim results for the six months ended 30 June 2025. Group revenue fell 41.8% year-on-year to HK$42.12 million, entirely generated by the footwear segment as the healthcare, financial-services and online medical units remained inactive. Despite the sharp top-line contraction, the Group booked a net profit attributable to shareholders of HK$20.60 million (H1 2024: HK$5.13 million loss), underpinned by a one-off HK$34.68 million gain from subsidiary disposals.

Gross profit narrowed 37.2% to HK$34.83 million, yet gross margin improved to 82.7% (H1 2024: 76.6%) on lower inventory provisions. Staff costs jumped to HK$27.56 million, absorbing 65.6% of revenue versus 29.9% a year earlier, while depreciation accounted for 12.4% of sales. Finance costs edged up to HK$1.33 million, mainly lease-related.

The footwear division operated 31 retail outlets in Hong Kong and 4 in Macau (up four and one outlets respectively versus June 2024). Weak consumer sentiment and economic uncertainty in Hong Kong were cited for the sales decline.

Balance-sheet metrics remain tight: current ratio stood at 0.61x, and total equity was negative HK$48.87 million. Cash and bank balances fell 2.6% since December to HK$22.40 million, while HK$21.53 million was owed to a director. A HK$50 million facility from the director underpins the Group’s going-concern assumption.

Subsequent to period-end, TATA Health completed the disposals of Shang Ying Retail Group and Shang Ying Capital Group in September 2025. Management expects the auditor’s prior disclaimer of opinion to be fully removed by FY-2027 following these actions.

No interim dividend was declared.